# FuturedMe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/futuredme

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: www.futuredme.com
- Total disclosed funding: $6.3M
- Latest round: Series A (Jun 6, 2019)
- Investors on record: 1

## About

FuturedMe Inc. is a biotechnology company focused on innovative drug design through its proprietary technology, CANDDY™, which aims to revolutionize treatment options for patients by targeting disease-related proteins directly.Founded in 2018, FuturedMe Inc. operates in Tokyo, Japan, specializing in drug discovery using its CANDDY™ technology, conceived at the Tokyo University of Science.In January 2026, FuturedMe Inc. raised JPY 150 million in venture funding from new investor UntroD Capital..FuturedMe Inc. specializes in innovative drug design through its core technology, CANDDY™, developed at the Tokyo University of Science under Professor Etsuko Miyamoto-Sato. CANDDY™ focuses on degrading disease-related proteins, addressing the needs of 20-30% of patients who lack effective medications tailored to their genetic profiles. The company targets the pharmaceutical industry and healthcare providers, facilitating the development of personalized medicine solutions for global markets, especially in regions with advanced healthcare systems.FuturedMe Inc. generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions focused on drug discovery. The revenue structure includes licensing agreements for the use of the CANDDY™ technology platform, milestone payments, royalties from sales of resulting drugs, and research and development reimbursement fees. CANDDY™ is central to FuturedMe's business model, driving strategic collaborations that enhance financial sustainability and market reach.FuturedMe Inc. plans to introduce new products utilizing the CANDDY™ technology platform to address unmet medical needs. The company aims to expand its market presence in North America and Europe by 2024, leveraging the JPY 686 million raised in Series A funding to support product development and market entry efforts. Recent funding will be instrumental in facilitating partnerships with additional pharmaceutical companies to enhance the reach and efficacy of its drug candidates.

## Funding rounds

- Series A, Jun 6, 2019, $6.3M — JAFCO Group

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A